AlphaMadera's AlphaVal page computes Regeneron Pharmaceuticals, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag REGN as undervalued, fairly valued, or overvalued.

What is Regeneron Pharmaceuticals, Inc.'s fair value?

Fair value for REGN is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value REGN?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from REGN's most recent reported fundamentals.

REGN - Regeneron Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $843.84 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 80% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Moderate

Trading 32.2% below fair value

Current Price $638.88

Bear Case $642.18 0.5% upside ($642.18 - $638.88) / $638.88 = 0.5% 8% stage 1 growth, 11% discount

Fair Value $941.99 47.4% upside ($941.99 - $638.88) / $638.88 = 47.4% 14% stage 1 growth, 11% discount

Bull Case $1,266.04 98.2% upside ($1,266.04 - $638.88) / $638.88 = 98.2% 18% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

13.8%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (14% base case)

Terminal Value % of EV 42%

Implied Market Multiple 18.0x

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $843.84 from 48 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $941.99 per share.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions